News
Deciphera Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Corporate Milestones
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH), a commercial-stage biopharmaceutical company developing innovative medicines to improve the lives of people with cancer, today provided a corporate
Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering
NANOBIOTIX (Paris:NANO) (Euronext: NANO – NASDAQ: NBTX – the ‘‘Company’’), a clinical-stage biotechnology company focused on developing first-in-class product candidates that use proprietary
Aurinia Pharmaceuticals to Present at Two Upcoming Virtual Healthcare Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the “Company”) today announced that members of the management team will participate in two upcoming virtual investor conferences and
Navidea Biopharmaceuticals to Present at the 2021 ICR Conference On January 14, 2021
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
Sangamo Therapeutics Announces Departure of Chief Financial Officer Sung Lee
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Chief Financial Officer Sung Lee is leaving the Company to pursue a new opportunity overseas. Mr. Lee’s
Puma Biotechnology to Present at the J.P. Morgan Healthcare Conference
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
Sangamo Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that management will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on
Deciphera Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference
Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) today announced that Steve Hoerter, President and Chief Executive Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference on Monday
Puma Biotechnology to Present at the H.C. Wainwright VIRTUAL BioConnect Conference
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of
IMV to Participate in Two Upcoming Investor Events
IMV Inc. (“IMV” or the “Corporation”) (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious
Clovis Oncology Submits Investigational New Drug Applications for Novel Peptide-Targeted Radionuclide FAP-2286 for Therapeutic and Imaging Clinical Trial
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the company has completed submission of two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for
Navidea Biopharmaceuticals Strengthens Board of Directors with the Appointment of Malcolm Witter
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today
IMV Reports Update on COVID-19 Vaccine Program
IMV Inc. (Nasdaq: IMV; TSX: IMV) (the “Company”), a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today
Clovis Oncology’s Rubraca® (rucaparib) Met the Primary Endpoint of Significantly Improving Progression-Free Survival vs. Chemotherapy in the ARIEL4 Randomized Phase 3 Treatment Study in Later-line Ovarian Cancer Patients with a BRCA mutation
Clovis Oncology, Inc. (NASDAQ: CLVS), today announced topline data from the randomized Phase 3 ARIEL4 study of Rubraca, which met its primary endpoint of improved investigator-assessed
Transgene and BioInvent Receive CTA Approval for Phase 1/2a Trial of Oncolytic Virus BT-001 in Solid Tumors
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and BioInvent International AB
European Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EU
Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Commission (EC) has approved PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)] for
Nanobiotix Announces Closing of Underwriters’ Option to Purchase Additional ADSs
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext: NANO – Nasdaq: NBTX – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today
Aurinia gibt Kooperations- und Lizenzvertrag mit Otsuka Pharmaceutical Co., Ltd. über die Entwicklung und Vermarktung von Voclosporin in Europa und Japan bekannt
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) („Aurinia“ oder das „Unternehmen“) gab heute den Abschluss eines Kooperations- und Lizenzvertrags mit Otsuka Pharmaceutical Co., Ltd. über die
Transgene Announces Financial Calendar for 2021
Regulatory News
Transgene (Paris:TNG) today announced its financial reporting dates for 2021:
March 10, 2021:
2020 Fiscal Year Results
April 27, 2021:
First
Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX:AUP) (“Aurinia” or the “Company”) today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for
Transgene Announces Investor Meetings for January 2021
Regulatory News:
Transgene (Paris:TNG) (Euronext Paris: TNG) today announces that Management will participate in the upcoming investor events set out below.
Transgene will meet institutional
Quantum Genomics Signs a Strategic Contract with Delpharm
Delpharm Group selected for large-scale production of firibastat tablets to support clinical phase and future commercial needs
Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a
Aurinia and Lonza Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (“Aurinia”) and Lonza Ltd. (SIX: LONN) ("Lonza") today announced they have expanded their exclusive manufacturing relationship. The parties
NANOBIOTIX Announces Closing of Global Offering and Full Exercise of Underwriters’ Option to Purchase Additional ADSs, Bringing Gross Proceeds of Global Offering to $113.3 Million
Regulatory News:
NANOBIOTIX (Paris:NANO) (Euronext : NANO – ISIN : FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Faran
Quantum Genomics to receive up to $12.1 million in upfront and milestone payments plus double-digit royalties on sales
Faran to receive an exclusive license to develop and commercialize firibastat